Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. - Cherney DZI; Belmar N; Bjornstad P; Chacko MM; Gunnarsson TP; Hodgin JB; Kretzler M; Pruijm M; Schytz PA; Tuttle KR (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025)